| 书目名称 | Checkpoint Responses in Cancer Therapy |
| 编辑 | Wei Dai |
| 视频video | http://file.papertrans.cn/225/224213/224213.mp4 |
| 概述 | First book to summarize recent advances in identifying components of cell-cycle checkpoints and validating the use of checkpoint proteins as targets for the development of anticancer drugs.Distinguish |
| 丛书名称 | Cancer Drug Discovery and Development |
| 图书封面 |  |
| 描述 | .Extensive research has uncovered a set of molecular surveillance mechanisms – commonly called “checkpoints” – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and |
| 出版日期 | Book 2008 |
| 关键词 | DNA; apoptosis; biotechnology; cancer; cancer research; cancer therapy; cell; cell cycle; checkpoint; chemoth |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-1-59745-274-8 |
| isbn_softcover | 978-1-61737-847-8 |
| isbn_ebook | 978-1-59745-274-8Series ISSN 2196-9906 Series E-ISSN 2196-9914 |
| issn_series | 2196-9906 |
| copyright | Humana Press 2008 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-15 01:12
发表于 2025-3-21 17:04:15
